Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Capital Expenditures (2019 - 2025)

Allogene Therapeutics' Capital Expenditures history spans 7 years, with the latest figure at $243000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 44.39% year-over-year to $243000.0; the TTM value through Sep 2025 reached $643000.0, up 4.05%, while the annual FY2024 figure was $694000.0, 54.22% down from the prior year.
  • Capital Expenditures for Q3 2025 was $243000.0 at Allogene Therapeutics, up from $44000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $19.0 million in Q3 2021 and bottomed at -$4.8 million in Q2 2021.
  • The 5-year median for Capital Expenditures is $257000.0 (2024), against an average of $1.5 million.
  • The largest YoY upside for Capital Expenditures was 4985.35% in 2021 against a maximum downside of 216.26% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $736000.0 in 2021, then soared by 129.89% to $1.7 million in 2022, then crashed by 89.3% to $181000.0 in 2023, then soared by 41.99% to $257000.0 in 2024, then decreased by 5.45% to $243000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Capital Expenditures are $243000.0 (Q3 2025), $44000.0 (Q2 2025), and $99000.0 (Q1 2025).